IDIOPATHIC PULMONARY FIBROSIS

This study is testing whether a drug called Senicapoc can slow the progression of scarring in the lungs for people with fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 participants will take either Senicapoc or a placebo pill three times…

This study is testing whether an oral medication called PIPE-791 can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. About 324 adults with IPF will take either PIPE-791 or a placebo pill for 26 weeks to see if th…

This study is testing if adding the antibiotic azithromycin to standard hospital treatment helps adults with a sudden, severe flare-up of a lung-scarring disease called IPF. Researchers want to see if the add-on drug shortens hospital stays and improves breathing. The trial will …

This study is testing if adding intravenous immunoglobulin (IVIG) to standard hospital care helps patients with idiopathic pulmonary fibrosis (IPF) who are hospitalized for a sudden, severe worsening of their lung disease. The main goal is to see if IVIG can reduce deaths in the …

This study is testing whether a daily oral medication called ifetroban can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. About 128 patients will take either the drug or a placebo pill for one year to see if it …

This study is testing whether a new drug called CAL101 can help slow down the worsening of lung function in people with idiopathic pulmonary fibrosis (IPF), a serious scarring lung disease. About 150 adults with IPF will be randomly assigned to receive either the CAL101 infusion …

This study is testing whether a new drug called ABBV-142 can help control Idiopathic Pulmonary Fibrosis (IPF), a serious disease that scars the lungs and makes breathing difficult. About 165 adults with IPF will be randomly assigned to receive either the new drug or a placebo for…

This study is testing an oral drug called H01 (hymecromone) in adults with progressive interstitial lung disease, a condition that causes scarring and thickening of lung tissue. The main goal is to see if H01 can reduce levels of a substance called hyaluronan in the blood, which …

This is the first human study testing a new oral medication called GNS-3545, which is being developed to treat idiopathic pulmonary fibrosis—a serious disease that causes progressive lung scarring. The study will enroll 72 healthy adults to check the drug's safety, how it moves t…

This is an early safety study to see if a drug called artesunate is safe and tolerable for people with Idiopathic Pulmonary Fibrosis (IPF), a serious disease that causes progressive lung scarring. About 15 participants will take the drug orally for 12 weeks at increasing doses to…

This study is testing a new oral drug called SB17170 for people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 30 patients will take either the drug or a placebo pill daily for 12 weeks to see if it helps slow the decline in lung function and imp…

This study is testing if a common heartburn medicine (lansoprazole) can slow down the progression of Idiopathic Pulmonary Fibrosis (IPF), a serious scarring lung disease. About 298 patients with IPF from across the UK will take either the real drug or a placebo (dummy pill) for a…

This study is testing if a combination of zinc and nicotinamide riboside supplements can help treat Idiopathic Pulmonary Fibrosis (IPF), a serious lung scarring disease. It aims to see if people with IPF can join and complete the entire trial from home, using video visits and loc…

This is a very early study to check if a new drug called SV001 is safe for people. It will be given to 53 healthy Chinese adults to see how their bodies handle it. The drug is being developed to treat Idiopathic Pulmonary Fibrosis, a serious disease that causes permanent scarring…

This early-phase study is testing a new, two-step transplant procedure for people who have both severe, end-stage lung disease and bone marrow failure. Doctors will first perform a lung transplant to improve breathing, followed by a bone marrow transplant from the same donor to t…

This study is testing whether an experimental drug called BI 765423 can help people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 71 adults with IPF will receive either the drug or a placebo via monthly IV infusions for 3 months, while researche…

This is a very early study to check the safety of a new drug called SRN001, which is being developed to treat a serious lung scarring disease called idiopathic pulmonary fibrosis. The study will give the drug to 30 healthy Korean and Caucasian men to see how their bodies react to…

This study is testing whether a new drug called MTX-463 can help slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 164 adults with IPF will receive either the drug or a placebo via IV infusion every four weeks for six months. The …

This study is testing whether an investigational drug called axatilimab can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. About 135 adults with IPF will receive either the drug or a placebo for 26 weeks to see …

This study is for people with progressive lung scarring diseases who previously took BI 1015550 in another trial. Researchers want to see how well people tolerate this medication long-term and whether it helps preserve lung function and delay serious health events. Participants t…

This study is testing a new wearable device called the C-mo System to see how well it can automatically detect and analyze coughs. About 245 adults and children (age 2+) with a troublesome cough from conditions like asthma or COPD will wear the device for one day and fill out que…

This is an early safety study for a new extended-release tablet called NAL ER in people with Idiopathic Pulmonary Fibrosis (IPF). The main goal is to see if increasing doses are safe and well-tolerated, and to check for any effects on breathing. It will involve a small group of 1…

This study aims to understand how a common IPF medication, pirfenidone, affects the levels of a newer drug, BI 1015550, in the bloodstream. It involves about 20 adults with idiopathic pulmonary fibrosis (IPF) who will take both drugs according to a specific schedule. Researchers …

This study aims to understand how inherited pulmonary fibrosis develops over time in family members who are at risk. Researchers will follow 750 healthy relatives of people with this lung-scarring disease for up to 10 years, using yearly questionnaires, lung scans, and blood test…

This study is creating a large collection of health information and biological samples from people with various scarring lung diseases. Researchers will use this 'biobank' to look for patterns, risk factors, and potential targets for future treatments. The goal is to better under…

This study aims to understand how often and how severely small airways are affected in people newly diagnosed with Idiopathic Pulmonary Fibrosis (IPF), a serious scarring lung disease. Researchers will observe 100 patients, using a special breathing test to measure small airway f…

This study aims to find genetic and biological markers that can predict when patients with idiopathic pulmonary fibrosis (IPF) might experience a rapid decline in lung function. Researchers will follow 500 patients over time, collecting blood samples, scans, and questionnaires ev…